Evidence map›Paper›PMID 30291335›Full record

Trial reportLeukemia2019

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.

Roch Houot, Guillaume Cartron, Fontanet Bijou, Sophie de Guibert, Gilles A Salles, Christophe Fruchart, Krimo Bouabdallah, Marie Maerevoet, Pierre Feugier, Steven Le Gouill and 14 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 16 institutions in 2 countries.

Roch HouotDepartment of Clinical Hematology, University Hospital of Rennes, Inserm 0203, University of Rennes, Rennes, France.
Guillaume CartronDepartment of Clinical Hematology, University Hospital of Montpellier, UMR CNRS 5235, University of Montpellier, Montpellier, France.
Fontanet BijouFrench Blood Institute, Bordeaux, France.
Sophie de GuibertDepartment of Clinical Hematology, University Hospital of Rennes, Inserm 0203, University of Rennes, Rennes, France.
Gilles A SallesDepartment of Hematology, Centre Hospitalier Lyon-Sud, Pierre Benite, France.ORCID http://orcid.org/0000-0002-9541-8666
Christophe FruchartInstitut d'Hématologie de Basse Normandie (IHBN), CHU, Caen, France.
Krimo BouabdallahHaematology, CHU de Bordeaux, Bordeaux, France.
Marie MaerevoetHematology, Institut Jules Bordet, Bruxelles, Belgium.
Pierre FeugierCHU et INSERM 954, Nancy Université, Vandoeuvre Les Nancy, France.
Steven Le GouillDepartment of Hematology, Nantes University Hospital and UMR892 INSERM, Nantes, France.
Hervé TillyCentre Henri Becquerel, Inserm U918, Université de Rouen, IRIB, Rouen, France.
Rene-Olivier CasasnovasHematology, University Hospital, Dijon, France.
Cécile Moluçon-ChabrotHematology Department, CHU Clermont Ferrand, Clermont-Ferrand, France.
Eric Van Den NesteDepartment of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Pierre ZacheeAZ GROENINGE, Kortrijk, Belgium.
Marc AndreHematology Department, CHU UCL NAMUR, Yvoir, Belgium.
Christophe BonnetClinical Hematology, CHU University of Liège, Liège, Belgium.
Corinne HaiounHôpital Henri Mondor, Unité Hémopathies Lymphoide, Créteil, France.
Achiel Van HoofGeneral Hospital St-Jan, Brugge, Belgium.
Koen Van EygenZNA Stuivenberg, Antwerp, Belgium.
Lysiane MolinaHematology, CHU de Grenoble, Grenoble, France.
Emmanuelle Nicolas-VirelizierHematology Department, Centre Léon Bérard, Lyon, France.
Philippe RuminyCentre Henri Becquerel, Inserm U918, Université de Rouen, IRIB, Rouen, France.
Franck MorschhauserUniversité de Lille/ hopital Claude Huriez, Lille, France. franck.morschhauser@chru-lille.fr.
Inserm · FRAZ Groeninge · BEAZ Sint-Jan · BECentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Léon Bérard · FRCentre National de la Recherche Scientifique · FRCHU Dinant Godinne UCL Namur · BECliniques Universitaires Saint-Luc · BEHôpital Lyon Sud · FRInstitut Jules Bordet · BEMaison des Sciences sociales et des Humanités de Dijon · FRUniversité de Lille · FRUniversity of Liège · BEZiekenhuisnetwerk Antwerpen Stuivenberg · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansLenalidomideLymphomaMaleMiddle AgedNeoplasm Recurrence, LocalRecurrenceAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalLenalidomideobinutuzumab

Identifiers

PMID30291335
OpenAlexW2894631140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.